The European Commission launched a formal antitrust investigation into Sanofi for alleged anticompetitive practices.
Regulators are probing whether the French drugmaker abused its dominant market position to disparage CSL Seqirus’s Fluad vaccine.
Sanofi allegedly promoted its own Efluelda vaccine through a misleading communication campaign targeting healthcare professionals in Germany and France.
The investigation focuses on claims that Sanofi misrepresented Fluad’s efficacy, contradicting findings from European and national health authorities.
Sanofi is cooperating with the probe and maintains it complied with all laws.